Arvinas, Inc. (ARVN) income statement
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.76−0.06 (-0.81%)
Close on Nov 18, 2026Market cap $442.34MP/E 42.3Yield –
Arvinas, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -5.7%
- Net margin
- 2.9%
- Return on equity, FY2025
- -16.2%
Financial strength
- Current ratio
- 7.91
- Debt to equity
- 0.00
- Debt to assets
- 0.1%
- Cash to current liabilities
- 114.3%
Valuation
- P/E ratio
- 42.3
- Price to sales
- 1.40
- Price to book
- 0.79
- Dividend yield
- –
See a number that looks wrong?